Do Urate Targets Influence CV Risk?
Researchers examine whether achieving treat-to-target serum urate levels with urate-lowering treatment affects long-term cardiovascular outcomes in patients with gout.
By
Kathryn Wighton
January 30, 2026
Clinical Scorecard: Do Urate Targets Influence CV Risk?
At a Glance
Category Detail
Condition Gout Key Mechanisms Achievement of serum urate targets is associated with reduced cardiovascular risk. Target Population Adults with newly diagnosed gout, particularly those with high cardiovascular risk. Care Setting Primary care and outpatient settings.
Key Highlights
Only 27% of patients achieved serum urate targets within 12 months. Achieving urate levels <6 mg/dL linked to 9% relative risk reduction for major adverse cardiovascular events (MACE). Stricter target of <5 mg/dL associated with 23% relative risk reduction. 99% of patients were prescribed allopurinol. 5-year cardiovascular event-free survival was 89% in the treat-to-target group. Guideline-Based Recommendations
Diagnosis
Monitor serum urate levels in patients with gout. Management
Implement urate-lowering treatment (ULT) using a treat-to-target approach. Monitoring & Follow-up
Regularly assess serum urate levels to ensure targets are met. Risks
Consider cardiovascular risk factors when managing gout. Patient & Prescribing Data
109,504 adults with newly diagnosed gout.
Allopurinol is the primary medication prescribed for urate-lowering.
Clinical Best Practices
Aim for serum urate levels <6 mg/dL in gout management. Follow a treat-to-target strategy to improve cardiovascular outcomes. Monitor for gout flares and adjust treatment as necessary. Related Resources & Content
